Cerebrotendinous Xanthomatosis News and Research

RSS

Cholesterol-processing enzyme could be therapeutic target to stave off neurologic diseases

An enzyme that helps break down cholesterol may also be a therapeutic target to stave off neurologic diseases, including Alzheimer's and a rare genetic disorder, according to a new study published in the Journal of Biological Chemistry.

2 Mar 2017

Study highlights the treatable causes of cerebellar ataxias

No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias. But in a few of these disorders, patients can be effectively treated with regimens such as prescription drugs, high doses of vitamin E and gluten-free diets, according to a study in the journal Movement Disorders.

24 Mar 2015

Retrophin reports net loss of $70.6 million for first quarter 2014

Retrophin, Inc. today reported its financial results for the quarter ended March 31, 2014.

14 May 2014

Retrophin acquires Manchester Pharmaceuticals

Retrophin, Inc. today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

27 Mar 2014